PSA
17
2
5
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.8%
2 terminated out of 17 trials
66.7%
-19.8% vs benchmark
6%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (17)
Smart Prostate Specific Antigen (PSA) Screening Study
EDRN Prostate MRI Biomarker Study
Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Marker Driven Selection of Patients for Prostate Biopsy and Management
RegisterPROS - a Registry for Prostate Cancers
Promoting CSD500 Use Among Women in Established Relationships
MRI Prostate for Chinese Men Being Screened for Prostate Cancer
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
PSA Glycomics Assay for Early Detection of Prostate Cancer
Therapeutic Study of Prostatitis With Elevated PSA
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV
Retrospective Chart Review of Treataprost Added to Antibiotic Treatment in Patients With Chronic Prostatitis
Prostate Impendance Test Project
Altered PSA Test Due to Possible Suspected Heterophilic Antibodies
Closing the Gap in Care in Seronegative Inflammatory Arthritis